At Ambrx, our mission is to discover and develop a pipeline of next gen ADCs engineered for stability and designed to treat cancers with a high unmet medical need.

Our internal pipeline is focused on creating next generation antibody drug conjugates (ADCs) for a variety of cancer indications, including our lead product candidate ARX517, a prostate-specific membrane antigen (PSMA) targeting ADC and ARX788, our lead product candidate targeting HER2. We have a twenty-year history of establishing collaborations with multiple pharmaceutical companies in additional indications and development projects.

Our team of dedicated professionals is bound by a culture and vision that embraces innovation, practicality, and accountability. Through these shared values, we pursue our mission of bringing next gen ADCs to patients in need of new targeted and stable treatment options. Visit our Careers page for information about joining our team.

Leadership

Chief Executive Officer,
President and Director

Chief Financial Officer

Chief Operating Officer

Chief Scientific Officer
and General Manager China

Chief Clinical Officer

Chief Technology Officer

Senior Vice President, General Counsel and Corporate Secretary

Chief Regulatory Officer

Vice President, Human Capital

Board of Directors

Stephen Glover

Chair

Daniel O’Connor

Member

Kate Hermans

Member

Janet Loesberg, Pharm. D

Member

Paul Maier

Member

Margaret R. Dalesandro, Ph.D.

Member

Scientific Advisory Board

Peter Schultz, Ph.D.

President and CEO of Scripps Research and a Professor of Chemistry.

Stuart Lutzker, M.D., Ph.D.

Jakob Dupont, M.D.

Melissa Starovasnik, Ph.D.

Luisa Salter-Cid, Ph.D., M.Sc.

Contact Us

Ambrx, Inc.
10975 North Torrey Pines Road La Jolla, CA 92037
(858) 875-2400

Investors
Mike Moyer
LifeSci Advisors
617-308-4306
mmoyer@lifesciadvisors.com

Media
Karissa Cross
Senior Account Executive, LifeSci Communications
kcross@lifescicomms.com